NAD+ Therapy: Benefits and Research

Understanding NAD+ Biology

Nicotinamide adenine dinucleotide (NAD+) is one of the most important molecules in human biology. It exists in two forms: NAD+ (oxidized) and NADH (reduced), and participates in over 500 enzymatic reactions. Its core functions include powering cellular energy production in the mitochondria (as a key player in the electron transport chain), serving as a substrate for sirtuins -- enzymes that regulate aging, inflammation, and metabolism, fueling PARP enzymes that repair damaged DNA, and acting as a signaling molecule that regulates circadian rhythm and immune function.

The NAD+ Decline Problem

NAD+ levels decrease dramatically with age. By age 60, most individuals have approximately 50% less NAD+ than they had at age 20. This decline is driven by increased DNA damage requiring PARP-mediated repair, upregulation of CD38 (a major NAD+ consuming enzyme associated with inflammation), decreased activity of NAMPT (the rate-limiting enzyme in NAD+ biosynthesis), and chronic inflammation that diverts NAD+ to immune signaling.

The consequences of NAD+ depletion include mitochondrial dysfunction and reduced cellular energy, impaired DNA repair and accumulated mutations, sirtuin inactivation leading to accelerated aging, and disrupted circadian rhythms and sleep quality.

NAD+ Restoration Strategies

Oral Precursors

NMN (Nicotinamide Mononucleotide) -- NMN is a direct precursor to NAD+ that requires only one enzymatic step for conversion. Human clinical trials have shown that oral NMN (250-1000 mg/day) increases blood NAD+ levels by 40-60%. The landmark 2024 study in Cell Metabolism demonstrated improved muscle insulin sensitivity and physical performance in prediabetic women taking 250 mg NMN daily for 10 weeks.

NR (Nicotinamide Riboside) -- NR is another NAD+ precursor that enters the salvage pathway at a slightly earlier step than NMN. Clinical trials show effective NAD+ boosting at 300-1000 mg/day. NR has more published human data than NMN and is FDA-approved as a dietary ingredient (branded as Niagen).

Injectable NAD+

Direct NAD+ administration bypasses the need for precursor conversion and achieves higher peak blood levels. Two routes are commonly used:

• IV infusion -- 250-750 mg infused over 2-4 hours. Produces the highest peak NAD+ levels but is time-consuming, expensive, and often causes significant nausea, chest tightness, and headache during infusion.
• Subcutaneous injection -- 50-200 mg per injection, self-administered daily or every other day. More practical than IV but still achieves meaningful NAD+ elevation. Side effects are milder but can include injection site pain (NAD+ solution can sting) and mild nausea.

Research Evidence for NAD+ Therapy

Animal Studies

The animal evidence for NAD+ restoration is robust. Studies in aged mice show that boosting NAD+ through NMN supplementation reversed age-related muscle decline and improved exercise capacity, restored blood vessel formation and endothelial function, improved cognitive function and reduced neuroinflammation, and extended lifespan in some models. A landmark 2013 study by David Sinclair's lab at Harvard showed that one week of NMN treatment in old mice restored mitochondrial function to levels similar to young mice.

Human Clinical Trials

Human evidence is growing rapidly. Published trials demonstrate that NMN and NR reliably increase blood NAD+ levels in humans, with improvements in muscle function, insulin sensitivity, walking speed in elderly subjects, and sleep quality and circadian alignment.

Practical NAD+ Protocol

Oral (NMN or NR)

• NMN: 250-1000 mg daily, taken in the morning
• NR: 300-1000 mg daily, taken in the morning
• Can be combined with other longevity compounds (resveratrol, quercetin)

Injectable NAD+

• Subcutaneous: 50-200 mg daily or every other day
• Start with 50 mg to assess tolerance (stinging at injection site is common)
• Use the Peptide Calculator Plus to determine volume for your concentration

Safety Considerations

NAD+ precursors (NMN, NR) have shown excellent safety profiles in human clinical trials at doses up to 1000+ mg/day. The most common side effects are mild GI discomfort and flushing. Injectable NAD+ carries additional considerations: injection site pain (NAD+ is acidic in solution), nausea during and after IV infusion, headache, and cost (significantly more expensive than oral precursors). There is a theoretical concern about NAD+ supporting cancer cell metabolism, as rapidly dividing cells require abundant NAD+. However, no clinical evidence of cancer promotion has been observed.